Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk

Nature Genetics

Volumn 44, Issue 1, 2012, Pages 58-61

  Broderick, Peter ^a   Chubb, Daniel ^a   Johnson, David C ^a   Weinhold, Niels ^b   Försti, Asta ^c   Lloyd, Amy ^a   Olver, Bianca ^a   Ma, Yussanne P ^a   Dobbins, Sara E ^a   Walker, Brian A ^a   Davies, Faith E ^a   Gregory, Walter A ^d   Child, J Anthony ^d   Ross, Fiona M ^e   Jackson, Graham H ^f   Neben, Kai ^b   Jauch, Anna ^b   Hoffmann, Per ^g   Mühleisen, Thomas W ^g   Nöthen, Markus M ^g,h   Moebus, Susanne ⁱ   Tomlinson, Ian P ^j   Goldschmidt, Hartmut ^b,k   Hemminki, Kari ^c,l   Morgan, Gareth J ^a   Houlston, Richard S ^a   more..

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e Wessex Regional Cytogenetic Laboratory   (United Kingdom)

^f ROYAL VICTORIA INFIRMARY   (United Kingdom)

^g UNIVERSITY OF BONN   (Germany)

^h GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

ⁱ UNIVERSITY HOSPITAL ESSEN   (Germany)

^j UNIVERSITY OF OXFORD   (United Kingdom)

^k National Centre of Tumour Diseases   (Germany)

^l LUND UNIVERSITY   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RISK; CHROMOSOME 2P; CHROMOSOME 3P; CHROMOSOME 7P; CONTROLLED STUDY; FEMALE; GENE LOCUS; GENE MAPPING; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

CASE-CONTROL STUDIES; CHROMOSOMES, HUMAN, PAIR 3; CHROMOSOMES, HUMAN, PAIR 7; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MULTIPLE MYELOMA; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN-SERINE-THREONINE KINASES; RISK FACTORS;

EID: 84655166569     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.993     Document Type: Article

References (43)

1. Kyle, R.A. & Rajkumar, S.V. Multiple myeloma. N. Engl. J. Med. 351, 1860-1873 (2004).
2. Palumbo, A. & Anderson, K. Multiple myeloma. N. Engl. J. Med. 364, 1046-1060 (2011).
3. Kyle, R.A. et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 346, 564-569 (2002). (Pubitemid 34438817)
4. Landgren, O. et al. Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. Blood 114, 791-795 (2009).
5. Altieri, A., Chen, B., Bermejo, J.L., Castro, F. & Hemminki, K. Familial risks and temporal incidence trends of multiple myeloma. Eur. J. Cancer 42, 1661-1670 (2006). (Pubitemid 44118762)
6. Morgan, G.J. et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 376, 1989-1999 (2010).
7. Power, C. & Elliott, J. Cohort profile: 1958 British birth cohort (National Child Development Study). Int. J. Epidemiol. 35, 34-41 (2006). (Pubitemid 43205440)
8. Schmermund, A. et al. Assessment of clinically silent atherosclerotic disease and established and novel risk factors for predicting myocardial infarction and cardiac death in healthy middle-aged subjects: rationale and design of the Heinz Nixdorf RECALL Study. Risk Factors, Evaluation of Coronary Calcium and Lifestyle. Am. Heart J. 144, 212-218 (2002). (Pubitemid 34879641)
9. Clayton, D.G. et al. Population structure, differential bias and genomic control in a large-scale, case-control association study. Nat. Genet. 37, 1243-1246 (2005). (Pubitemid 41568707)
10. Price, A.L. et al. Principal components analysis corrects for stratification in genomewide association studies. Nat. Genet. 38, 904-909 (2006). (Pubitemid 44141658)
11. Pettiti, D. Meta-analysis Decision Analysis and Cost-Effectiveness Analysis (Oxford University Press, New York, USA, 1994).
12. Tomlinson, I.P. et al. A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat. Genet. 40, 623-630 (2008). (Pubitemid 351601204)
13. Jung, C.H., Ro, S.H., Cao, J., Otto, N.M. & Kim, D.H. mTOR regulation of autophagy. FEBS Lett. 584, 1287-1295 (2010).
14. Liang, C. & Jung, J.U. Autophagy genes as tumor suppressors. Curr. Opin. Cell Biol. 22, 226-233 (2010).
15. Ocio, E.M., Mateos, M.V., Maiso, P., Pandiella, A. & San-Miguel, J.F. New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncol. 9, 1157-1165 (2008).
16. Taddesse-Heath, L., Meloni-Ehrig, A., Scheerle, J., Kelly, J.C. & Jaffe, E.S. Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of plasmablastic features. Mod. Pathol. 23, 991-999 (2010).
17. Dib, A., Gabrea, A., Glebov, O.K., Bergsagel, P.L. & Kuehl, W.M. Characterization of MYC translocations in multiple myeloma cell lines. J. Natl. Cancer Inst. Monogr. 39, 25-31 (2008).
18. Huang, A. et al. Identification of a novel c-Myc protein interactor, JPO2, with transforming activity in medulloblastoma cells. Cancer Res. 65, 5607-5619 (2005). (Pubitemid 40911161)
19. Maertens, G.N., Cherepanov, P. & Engelman, A. Transcriptional co-activator p75 binds and tethers the Myc-interacting protein JPO2 to chromatin. J. Cell Sci. 119, 2563-2571 (2006). (Pubitemid 44070437)
20. Blake, D.J. et al. β-dystrobrevin, a member of the dystophin-related protein family. Proc. Natl. Acad. Sci. USA 95, 241-246 (1998). (Pubitemid 28103938)
21. Matys, V. et al. TRANSFAC and its module TRANSCompel: transcriptional gene regulation in eukaryotes. Nucleic Acids Res. 34, D108-D110 (2006).
22. Ferretti, V. et al. PReMod: a database of genome-wide mammalian cis-regulatory module predictions. Nucleic Acids Res. 35, D122-D126 (2007). (Pubitemid 46056182)
23. Walker, B.A. et al. Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood 108, 1733-1743 (2006). (Pubitemid 44316144)
24. Stranger, B.E. et al. Genome-wide associations of gene expression variation in humans. PLoS Genet. 1, e78 (2005).
25. Stranger, B.E. et al. Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science 315, 848-853 (2007).
26. Fonseca, R. et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 23, 2210-2221 (2009).
27. Dewald, G.W., Kyle, R.A., Hicks, G.A. & Greipp, P.R. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 66, 380-390 (1985). (Pubitemid 15007030)
28. Debes-Marun, C.S. et al. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 17, 427-436 (2003). (Pubitemid 36266921)
29. Walker, B.A. et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood 116, e56-e65 (2010).
30. Landgren, O. & Weiss, B.M. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis. Leukemia 23, 1691-1697 (2009).
31. Enciso-Mora, V. et al. A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3). Nat. Genet. 42, 1126-1130 (2010).
32. Crowther-Swanepoel, D. et al. Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nat. Genet. 42, 132-136 (2010).
33. Chiecchio, L. et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia 20, 1610-1617 (2006). (Pubitemid 44264105)
34. Neben, K. et al. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica 95, 1150-1157 (2010).
35. Wuilleme, S. et al. Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma. Leukemia 19, 275-278 (2005). (Pubitemid 40220593)
36. Purcell, S. et al. PLINK: a tool set for whole-genome association and populationbased linkage analyses. Am. J. Hum. Genet. 81, 559-575 (2007). (Pubitemid 47330214)
37. Higgins, J.P. & Thompson, S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 21, 1539-1558 (2002). (Pubitemid 34746062)
38. Ioannidis, J.P., Ntzani, E.E. & Trikalinos, T.A. 'Racial' differences in genetic effects for complex diseases. Nat. Genet. 36, 1312-1318 (2004). (Pubitemid 39577941)
39. Willer, C.J., Li, Y. & Abecasis, G.R. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 26, 2190-2191 (2010).
40. Houlston, R.S. & Ford, D. Genetics of coeliac disease. QJM 89, 737-743 (1996). (Pubitemid 26345113)
41. Myers, S., Bottolo, L., Freeman, C., McVean, G. & Donnelly, P. A fine-scale map of recombination rates and hotspots across the human genome. Science 310, 321-324 (2005). (Pubitemid 41457199)
42. Gabriel, S.B. et al. The structure of haplotype blocks in the human genome. Science 296, 2225-2229 (2002). (Pubitemid 34680308)
43. Cuzick, J. A Wilcoxon-type test for trend. Stat. Med. 4, 87-90 (1985). (Pubitemid 15142530)